Skip to main content
Registrieren
Springer Medizin Österreich
SUCHE
MENÜ 1 2 3 4
nach oben

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2015

01.09.2015 | short review

ASH 2014: novel strategies in the management of classical Hodgkin’s lymphoma

verfasst von: MD Daniel Heintel

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

This review discusses promising new approaches in the management of classical Hodgkin’s lymphoma that have been recently presented at the annual ASH meeting. Novel insights regarding risk-adapted, tailored therapy as well as improved treatment strategies in relapsed/refractory disease have been presented.
Vorheriger Artikel Aggressive lymphoma: news on ASH 2014
Nächster Artikel ASH 2014 highlights: new therapeutic concepts for T cell lymphomas
Literatur
1.
Mounier N, Gisselbrecht C. Decision-making in the management of adult classical Hodgkin’s lymphoma: determining the optimal treatment. Expert Rev Hematol. 2015;8(2):205–16. CrossRefPubMed
2.
Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52. CrossRefPubMed
3.
Gallamini A, Barrington SF, Biggi A, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014;99(6):1107–13. PubMedCentralCrossRefPubMed
4.
Mounier N, Brice P, Bologna S, Lymphoma Study Association (LYSA), et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Ann Oncol. 2014;25(8):1622–8. CrossRefPubMed
5.
Federico M, Luminari S, Iannitto E, HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009;27(5):805–11. CrossRefPubMed
6.
Viviani S, Zinzani PL, Rambaldi A, Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203–12. CrossRefPubMed
7.
Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(10):943–52. CrossRefPubMed
8.
Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9. PubMedCentralCrossRefPubMed
9.
Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma. a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–56. CrossRefPubMed
10.
Ansell SM Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(7):771–9. CrossRefPubMed
11.
Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616–23. CrossRefPubMed
12.
Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119(7):1665–70. PubMedCentralCrossRefPubMed
Metadaten
Titel
ASH 2014: novel strategies in the management of classical Hodgkin’s lymphoma
verfasst von
MD Daniel Heintel
Publikationsdatum
01.09.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0230-8

Weitere Artikel der Ausgabe 3/2015

memo - Magazine of European Medical Oncology 3/2015 Zur Ausgabe

Case report

A 59-year-old patient with somatic type malignancy as a relapse of testicular tumor after 28 years

comment

Notes on breast cancer prevention and screening

short review

ASH 2014 highlights: new therapeutic concepts for T cell lymphomas

short review

Chronic lymphocytic leukemia: ASH update 2014

short review

Changing treatment paradigms in lymphoma: new targets and new drugs

short review

Indolent lymphoma at ASH 2014: new kids on the block (iDrugs)